Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELCTLN: L-ornithine L-aspartate in adult-onset citrullinemia (citrin deficiency)
jRCTs031180195Completed
- Sponsor
- Citrin Foundation
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of l-ornithine l-aspartate in citrullinemia type 2 (CTLN2), citrin deficiency, hyperammonemia and 1 more, sponsored by Citrin Foundation. Primary endpoints: Change in plasma ammonia levels and Change in plasma citrulline levels. Started Apr 2019; status: completed.
02
Drugs
l-ornithine l-aspartate
03
Conditions
citrullinemia type 2 (CTLN2)citrin deficiencyhyperammonemiahepatic encephalopathy (HE)
Beyond the preview
Go deeper on jRCTs031180195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180195.